Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1-16. (canceled).

17. (currently amended) A method of treating ~~asthma, inflammation, inflammatory skin disease, psoriasis, atopic dermatitis, contact dermatitis, rheumatoid arthritis, osteoarthritis, chronic obstructive pulmonary disease, chronic pulmonary inflammatory disease,~~ inflammatory bowel disease or Crohn's Disease, ~~chronic bronchitis, allergic rhinitis, arthritis, joint inflammation, inflammation of the eye, allergic responses in the eye, gouty arthritis, arthritic condition, adult respiratory distress syndrome, acute respiratory distress syndrome, reperfusion injury, graft vs host reaction, allograft rejection, systemic lupus erythematosus, leukemia, or neuyrogenic inflammatory disease associated with irritation or pain,~~ which comprises administering to a patient a therapeutically effective amount of enantiomerically pure (-)-3-(3,4-dimethoxyphenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound inhibits PDE4.

18-23. (canceled).

24. (currently amended) The method of claim 17 further comprising administering to ~~a~~ the patient a therapeutically effective amount of an ~~antihistamine,~~ anti-inflammatory drug, non-steroid anti-inflammatory drug, steroid, ~~anti-cancer agent,~~ hematopoietic growth factor, cytokine, stem cell transplantation, or kinase inhibitor.

25-26. (canceled).

27. (previously presented) The method of claim 17 wherein the patient is a mammal.

28. (previously presented) The method of claim 17 wherein the enantiomerically pure (-)-3-(3,4-dimethoxyphenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide is administered parenterally, transdermally, mucosally, nasally, buccally, sublingually, topically, or orally.

29. (previously presented) The method of claim 17 wherein the therapeutically effective amount is from about 1 mg to about 5,000 mg per day.

30. (previously presented) The method of claim 29 wherein the therapeutically effective amount is from about 10 mg to about 2,500 mg per day.

31. (previously presented) The method of claim 30 wherein the therapeutically effective amount is from about 100 mg to about 1,200 mg per day.

32. (previously presented) The method of claim 29, wherein the enantiomerically pure (-)-3-(3,4-dimethoxyphenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide is administered twice a day.

33-46. (canceled).

47. (new) The method of claim 17, wherein the patient is a human.